-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the last day of November, Horizon Therapeutics' board of directors confirmed that it was working with pharmaceutical giant Amgen (AMGN.
US), Sanofi (SNY.
US) and Johnson & Johnson (JNJ.
US), a subsidiary of Janssen Global Services, each a "Potential Offeror", conducted highly preliminary discussions
.
However, Horizon, which makes drugs to treat rare, autoimmune and severe inflammatory diseases, added that it may or may not result in an offer
of the company's entire share capital.
According to public information, Amgen declined to comment on the negotiations on the acquisition of Horizon, and Sanofi and Janssen Global Services, a subsidiary of Johnson & Johnson, have not responded
.
Horizon Therapeutics is a commercially developed biotechnology company focused on developing drugs for the treatment of rare, autoimmune, and severe inflammatory diseases to meet urgent needs
in these disease areas.
Horizon's revenue grew 12-fold
from $297 million in 2014 to $3.
565 billion in 2022.
At present, Horizon's US stock market value closed at $17.
849 billion, and the stock price soared 30% after hours, with an after-hours market value of about $23.
267 billion
.
Horizon acknowledges that preliminary discussions regarding potential offers may not be published, published, or distributed, directly or indirectly, in whole or in part, in any jurisdiction that would violate the applicable laws
of that jurisdiction.
Depending on the existing market capitalization as well as the potential premium, the purchase price of the transaction could exceed $20 billion
.
The results of this merger may be announced during the 2023 JPM conference, and it is worth watching which
big pharmaceutical company Horizon will be owned.
Looking back on November, what major events have happened to pharmaceutical companies at home and abroad? Let's
take stock.
1.
The heads of the four major sectors of AstraZeneca China "arrived"
On November 23, Guan Dongmei officially became the new vice president and head of the cardiovascular, renal and metabolic business unit of AstraZeneca China, and reported directly to Lai Minglong, general manager of AstraZeneca China
, as a member of the China management team.
It is reported that Guan Dongmei graduated from Fujian University of Chinese Medicine, has a master's degree in medicine, has entered the pharmaceutical industry for more than 20 years, and previously worked in many well-known pharmaceutical companies such as GSK, Roche, Bristol-Myers Squibb, etc.
, including marketing director, immuno-oncology business leader, virology business department head, product planning management team leader, special drug business leader, etc
.
In her last role, Guan Dongmei was the head of GSK's China product planning management team and the head of specialty medicine, where she led the team to more than triple the business growth and achieve new product launch
in two years.
After Guan Dongmei officially took over AstraZeneca's business in the field of cardiovascular, renal and metabolic therapy in China, she will also focus on AstraZeneca's whole-course management and innovative solutions
in the field of chronic disease treatment.
So far, the relevant heads of the four major sectors of AstraZeneca's China business structure have been put in place
.
2.
Sanofi's former CEO will take over as Biogen
On November 10, Biogen announced the appointment of former Sanofi CEO Christopher Viehbacher as president, CEO and board member, effective
November 14.
Chris Viehbacher
Weibach previously spent 20 years at GlaxoSmithKline before taking over as Sanofi's global CEO for six years in December 2008
.
During his tenure, he restructured Sanofi's business, including terminating several promising projects, laying off employees, closing several French pharmaceutical plants, and entering the U.
S.
market through mergers and
acquisitions.
Notable achievements include the Dupilumab partnership with Regeneron and the $20.
1 billion acquisition of Genzyme and its rare disease drugs
in 2011.
In September this year, Biogen/Eisai's other Aβ drug, Lecanemab, reached the primary endpoint and was prioritized for review by the BLA with a PDUFA date of January 6
, 2023.
This may be the key to Weibach's ability to lead Biogen back to morale
.
3.
The former CEO of Novartis will take the helm of Seagen
On November 10, local time, Seagen announced the appointment of David R.
Epstein as chief executive officer (CEO) and board member
.
Seagen also announced the appointment of Roger Dansey as president
of research and development.
Dansey has served as Seagen's Chief Medical Officer since 2018 and in May 2022, he was named interim CEO
.
Next, Dansey will report to the new CEO, Epstein
.
David R.
Epstein
The new CEO, Epstein, has more than 30 years of experience in the pharmaceutical industry, having spent more than 25 years at Novartis, where he established the Oncology business unit and was CEO of Novartis Pharmaceuticals for 6 years
.
Prior to joining Seagen, he was the Managing Partner
of Flagship Pioneering.
Seagen, formerly a Seattle genetics company, was founded in 1997 by Bristol-Myers Squibb executive Clay Siegall and listed on
the NASDAQ in 2001.
In September 2021, it officially changed its name to Seagen
.
As a pioneer in the ADC space, Seagen currently has 3 self-developed listed ADCs, 1 co-developed listed ADC, and 4 ADCs
in clinical stages.
It is worth mentioning that in July this year, the industry reported that Merck intends to acquire Seagen for $40 billion
.
But later, the two companies had not yet agreed on a price, leading to deadlock in acquisition talks
.
If successful, it could be the largest acquisition in the pharmaceutical industry of the year
.
4.
Boehringer Ingelheim welcomes a new CMO
On November 3, former Novartis executive Lykke Hinsch Gylvin said she would join Boehringer Ingelheim as CMO and head of global medicine
.
Since Mehdi Shahidi, MD, left in February, Boehringer Ingelheim has been looking for a new chief medical officer (CMO
).
It is understood that the new CMO Lykke Hinsch Gylvin previously served as vice president of global medical franchise and head of
neuroscience at Novartis.
Prior to that, she spent four years at AstraZeneca and held leadership positions
at Roche, Novo Nordisk and Lundbeck.
5.
A number of Biotechs streamline pipelines and implement downsizing plans
On November 14, NexImmune, a Biotech developer of next-generation cell therapies, announced a strategic change to focus on the AIM INJ platform program, suspending clinical programs NEXI-001 and NEXI-003, and reducing its 74-person workforce by 30 percent, primarily affecting people involved in the AIM ACT program
.
On the same day, a number of biotech companies announced plans to streamline pipelines or reduce staff to extend business hours
.
For example, Harpoon, a cancer immunotherapy company that develops novel T-cell therapies, announced that it will fully focus resources on the development of three programs that have entered the clinic (HPN217, HPN328, and HPN601), while reducing staff by 45% to reduce operating expenses, and expects existing assets to be maintained through the end of 2023; Oncology biotech company Prelude announces reprioritization of its clinical pipeline to discontinue in-house development of the PRMT5 program; Clinical-stage pharmaceutical Neoleukin announced that it is halting development of its drug candidate, NL-201, a novel IL-2/IL-15 agonist, and reducing its workforce by approximately 40% to extend the cash runway through the second half of
2025.
1.
General Manager of Hehuang Pharmaceutical will leave his post
Recently, Hehuang Pharmaceutical announced an important personnel change
.
Marek Kania, Executive Vice President, General Manager and Chief Medical Officer (International) of Hutchison Pharmaceutical, will gradually step down from his position
at Hutchison Pharmaceutical.
Shi Ming, Executive Vice President, Head of R&D and Chief Medical Officer (China), will be responsible for global R&D and clinical development
.
Hutchison said that under Shi's leadership, the company will continue to focus highly on the regulatory application and further development of its leading international drug fruquintinib, including the upcoming submission to the US Food and Drug Administration
, following the results of the successful multi-center clinical trial of FRESCO-2 in August 2022.
Not long ago, Hutchison announced a strategy to focus on obtaining late-stage pipeline regulatory approvals, and the above personnel changes are also part of
the strategic focus adjustment.
2.
Zai Lab appoints the Chief Scientific Officer
On November 8, Zai Lab's official website announced the appointment of Dr.
Huang Qinhua as the Chief Science Museum, effective
immediately.
Huang will report to Josh Smiley, the Company's Chief Operating Officer, and will become a core member of
the Company's Management Committee.
He will lead and manage the company's drug discovery and translational medicine efforts
.
From 2006 to 2015, Dr.
Huang worked at Pfizer as one of the firm's oncology designers, focusing on small molecule drug discovery
.
He then worked at Zentalis Pharmaceuticals from March 2015 to October 2022, where he held a number of different roles and assumed increasingly important responsibilities
.
Since October 2020, he has served as Senior Vice President of Drug Discovery Research at Zentalis, where he is responsible for managing the company's drug portfolio and pipeline, building the drug discovery platform, leading the discovery of multiple new clinical candidates, and managing translational research to support clinical development
.
In this role, Dr.
Huang was the lead inventor of several clinical compounds, including lorlatinib
.
Lolatinib is an anaplastic lymphoma kinase inhibitor (ALKi) that was approved
by the US Food and Drug Administration in 2018.
Based on the discovery and development of lorlatinib, Dr.
Huang received the 2021 "Hero of Chemistry" award
from the American Chemical Society.
Dr.
Huang holds a Ph.
D.
in organic chemistry from Iowa State University and completed his postdoctoral research
at the University of Chicago.
3.
Chairman of BeiGene's Change Scientific Advisory Board
On November 21, BeiGene announced that effective November 20, 2022, Dr.
Alessandro Riva has been appointed Co-Chair
of the Council's Scientific Advisory Committee.
The original chairman, Dr.
Corazon D.
Sanders, will no longer serve as co-chair of the Scientific Advisory Board, but will continue to serve on
the Scientific Advisory Board.
4.
Hua Medicine appoints Chief Scientific Officer
On November 24, Hua Medicine appointed Dr.
Li Changhong as the company's new Chief Scientific Officer and reported to Dr.
Chen Li, founder and CEO of Hua Medicine, who will no longer concurrently serve as Chief Scientific Officer
.
It is reported that Dr.
Li Changhong is a senior metabolic disease researcher, a former member of the Institute of Diabetes, Obesity and Metabolism at the Perelman School of Medicine of the University of Pennsylvania, and a professional member of
the American Diabetes Association (ADA).
Dr.
Li Changhong received his M.
D.
from Beijing Medical University (now Peking University Health Science Center) and has more than 20 years of experience
in islet function and metabolism and translational medicine.
Dr.
Li has worked for more than 18 years
at Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania.
During this time, Dr.
Li served as an assistant professor of research at the University of Pennsylvania and Children's Hospital of Philadelphia, and worked extensively with
renowned pediatric endocrinologists Dr.
Charles Stanley and Dr.
Franz Matschinsky.
